Edition:
United States

Key Developments: Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

80.83EUR
11:35am EDT
Change (% chg)

€-1.24 (-1.51%)
Prev Close
€82.07
Open
€81.36
Day's High
€81.56
Day's Low
€80.00
Volume
524,164
Avg. Vol
525,867
52-wk High
€102.30
52-wk Low
€70.68

Search Stocks

Latest Key Developments (Source: Significant Developments)

Merck KGaA publishes Chinese Phase III study for Erbitux - Reuters
Monday, 25 Apr 2016 02:11am EDT 

Merck KGaA:Says phase III tailor landmark study demonstrates significant benefits of erbitux in combination with folfox over folfox alone - Reuters.Says marks a major milestone of merck’s oncology strategy including expansion in growth markets.Says will work with relevant authorities to make erbitux available for patients in china as a first - line treatment as soon as possible.  Full Article

Merck KGaA issues FY 2016 outlook, to propose FY 2015 dividend
Tuesday, 8 Mar 2016 01:00am EST 

Merck KGaA:Expects slight organic sales growth in 2016, low double-digit pct increase in adjusted EBITDA.Proposes annual dividend of 1.05 euros per share vs poll avg of 1.09 euros per share.FY 2016 revenue 15,310 million euros - Thomson Reuters I/B/E/S.FY 2016 EBITDA 4,314 million euros - Thomson Reuters I/B/E/S.  Full Article

Merck KGaA, Darmstadt, Germany, Pfizer and Verastem announce combination trial of Avelumab and VS-6063 in ovarian cancer
Thursday, 3 Mar 2016 07:00am EST 

Merck KGaA Merck KGaA, Darmstadt, Germany, Pfizer and Verastem:Says have entered into an agreement to evaluate avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Verastem's VS-6063, an investigational focal adhesion kinase inhibitor, in patients with advanced ovarian cancer.Financial terms of the agreement have not been disclosed.Phase I/Ib clinical trial is expected to begin in the second half of 2016.  Full Article

Merck KGaA and Biocartis to collaborate on new liquid biopsy technology for RAS biomarker testing
Wednesday, 6 Jan 2016 07:00pm EST 

Merck KGaA:Merck and Biocartis to collaborate on new liquid biopsy technology for RAS biomarker testing.Merck becomes first pharmaceutical company to collaborate with multiple diagnostic providers to support RAS biomarker testing.Collaboration allows Merck to provide complementary molecular testing solutions to various laboratory segments.  Full Article

Merck KGaA,Darmstadt, Germany, Pfizer and Syndax announces collaboration to evaluate combination of avelumab and entinostat in ovarian cancer
Monday, 4 Jan 2016 08:00am EST 

Merck KGaA:Says Co, Darmstadt, Germany, Pfizer and Syndax announces collaboration to evaluate combination of avelumab and entinostat in ovarian cancer.Says financial terms of the agreement were not disclosed.This is an exclusive agreement between the alliance and syndax to study the combination of two investigational agents in ovarian cancer.Says syndax will be responsible for conducting the phase ib/ii clinical trial in ovarian cancer.  Full Article

Merck KGaA acquires Ormet Circuits, no purchase price disclosed
Sunday, 13 Dec 2015 07:00pm EST 

Merck KGaA:Acquires Ormet Circuits, no purchase price disclosed.Says acquisition to enhance position as semiconductor materials supplier.Merck says deal complements existing integrated circuit materials business unit.  Full Article

Merck KGaA to invest extra 250 million euros in pharma pipeline
Wednesday, 9 Dec 2015 07:00pm EST 

Merck KGaA:Plans to invest extra 250 million euros in pharma pipeline.Sees one-off integration costs from sigma-aldrich of 400 million euros over 4 yrs.Expects cost savings of 90 million euros from sigma-aldrich takeover‍​.  Full Article

Merck KGaA, Threshold drug fails in late-stage cancer trials - Reuters
Sunday, 6 Dec 2015 10:11pm EST 

Merck KGaA:Merck KGaA MRCG.DE and development partner Threshold Pharmaceuticals THLD.O said their experimental cancer drug evofosfamide failed to extend lives in two late-stage clinical studies, a major setback for both firms - RTRS.Evofosfamide did not meet the main goal of improving survival in patients suffering from advanced pancreatic cancer and advanced soft tissue sarcoma, prompting the two companies to give up exploring the drug's use against these cancer forms. - RTRS.Merck said on Monday it would focus efforts on more promising candidates in its drug pipeline and would soon decide about evofosfamide's overall future - RTRS.The new disappointment leaves CEO-designate Stefan Oschmann, a pharmaceuticals expert, with a narrow drug development pipeline that rests mainly on cancer immune therapy avelumab, jointly developed with Pfizer - RTRS.  Full Article

Merck KGaA decides not to pursue evofosfamide further in soft tissue sarcoma and pancreatic cancer
Sunday, 6 Dec 2015 07:00pm EST 

Merck KGaA:Merck KGaA MRCG.DE and development partner Threshold Pharmaceuticals said their experimental cancer drug evofosfamide failed to show the desired effects in two late stage studies.Evofosfamide did not meet the main goal of improving overall survival in patients suffering from advanced pancreatic cancer and advanced soft tissue sarcoma, prompting the two companies to give up exploring the drug's use against the these cancer forms.  Full Article

Merck KGaA raises FY 2015 outlook
Wednesday, 11 Nov 2015 07:00pm EST 

Merck KGaA:Forecast for FY 2015 lifted thanks to good operational performance and Sigma-Aldrich acquisition.For FY 2015 expects Group net sales to increase overall to between 12.6 billion euros and 12.8 billion euros (previously: 12.3 billion - 12.5 billion euros).EBITDA pre exceptionals are forecast to come in between 3,580 million and 3,650 million euros in FY 2015 (previously: 3,450 million – 3,550 million euros).Earnings per share pre exceptionals are expected to be between 4.80 and 4.95 euros (previously: 4.60 – 4.80 euros).  Full Article

BRIEF-Merck sees negative FX effects for 2016

* Says sees significant nominal and slight organic growth in sales this year

Search Stocks